Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Emergent BioSolutions Inc.EBS · Entity 5902 | Director | April 30, 2026 | May 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Emergent BioSolutions Inc.
Report date April 30, 2026 · Filed May 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 123,761 |
Reported balance
After 2026-04-30 transaction · row 1
1 source rowRow 1 · 2026-04-30 · Grant · Acquired 25,344 · Balance 123,761 F1: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.99 · Expires 2033-04-30 | Direct | 11,296 |
Reported balance
After 2026-04-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-30 · Grant · Acquired 11,296 · Balance 11,296 F2: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. F3: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.
F2: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.
F3: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 30, 2026 Filed May 4, 2026 21:28 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantStock Option (Right to Buy) · Derivative | 11,296 | $0.00 Strike: $7.99 | $0.00 |
DisclosureSEC source: 0001380177-26-000004 · wk-form4_1777930129.xml · derivative · entry 2 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,296 Underlying: Common Stock · 11,296 shares Expires 2033-04-30 F2 · derivative.exercise_date: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. F3 · derivative.underlying_shares: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| April 30, 2026 Filed May 4, 2026 21:28 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 25,344 | $0.00 | $0.00 |
DisclosureSEC source: 0001380177-26-000004 · wk-form4_1777930129.xml · nonDerivative · entry 1 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,761 F1 · shares: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 23:01 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,748 | $0.00 Strike: $5.02 | $0.00 |
DisclosureSEC source: 0001380177-25-000006 · wk-form4_1765321258.xml · derivative · entry 5 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,748 shares Expires 2031-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, as compensation for Board and Committee service. The shares underlying the options exercised were fully vested on May 22, 2025. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 23:01 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 14,884 | $11.90 | $177,086.86 |
DisclosureSEC source: 0001380177-25-000006 · wk-form4_1765321258.xml · nonDerivative · entry 4 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,417 F4 · price: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $11.88 to $11.97. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 23:01 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 10,864 | $11.90 | $129,257.70 |
DisclosureSEC source: 0001380177-25-000006 · wk-form4_1765321258.xml · nonDerivative · entry 3 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,301 F3 · shares: Represents shares of common stock sold solely to satisfy the option exercise price and applicable taxes associated with the option exercise. F4 · price: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $11.88 to $11.97. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 23:01 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 25,748 | $5.02 | $129,254.96 |
DisclosureSEC source: 0001380177-25-000006 · wk-form4_1765321258.xml · nonDerivative · entry 2 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,165 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 23:01 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 7,100 | $12.11 | $85,990.23 |
DisclosureSEC source: 0001380177-25-000006 · wk-form4_1765321258.xml · nonDerivative · entry 1 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,417 F1 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. F2 · price: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $12.11 to $12.12. Read SEC document |
| April 30, 2025 Filed May 3, 2025 00:31 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantStock Option (Right to Buy) · Derivative | 15,824 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0001367644-25-000111 · wk-form4_1746232297.xml · derivative · entry 2 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,572 Underlying: Common Stock · 15,824 shares Expires 2032-04-29 F2 · derivative.exercise_date: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. F3 · derivative.underlying_shares: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| April 30, 2025 Filed May 3, 2025 00:31 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 34,403 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-25-000111 · wk-form4_1746232297.xml · nonDerivative · entry 1 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,517 F1 · shares: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Read SEC document |
| May 23, 2024 Filed May 29, 2024 01:14 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantStock Option (Right to Buy) · Derivative | 25,748 | $0.00 Strike: $5.02 | $0.00 |
DisclosureSEC source: 0001367644-24-000076 · wk-form4_1716945249.xml · derivative · entry 2 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,748 Underlying: Common Stock · 25,748 shares Expires 2031-05-22 F2 · derivative.exercise_date: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. F3 · derivative.underlying_shares: The number of options granted was determined by dividing half of the total non-employee director compensation value by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| May 23, 2024 Filed May 29, 2024 01:14 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 17,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-24-000076 · wk-form4_1716945249.xml · nonDerivative · entry 1 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,114 F1 · shares: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Read SEC document |
| May 25, 2023 Filed May 30, 2023 23:06 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 33,847 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-23-000106 · wk-form4_1685487966.xml · nonDerivative · entry 1 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,684 F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan, as amended and restated. These restricted stock units vest in one installment beginning on the day prior to the first anniversary of the date of grant assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| November 25, 2022 Filed Nov 29, 2022 20:26 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 1,912 | $11.94 | $22,829.28 |
DisclosureSEC source: 0001367644-22-000148 · wf-form4_166975354620077.xml · nonDerivative · entry 1 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,837 F1 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. Read SEC document |
| May 26, 2022 Filed May 31, 2022 20:17 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 8,446 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-22-000090 · wf-form4_165402821355835.xml · nonDerivative · entry 1 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,749 F1 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of: (i) the day prior to the first anniversary of the date of grant, or (ii) the day prior to annual shareholder meeting; assuming continued service with the company. Read SEC document |
| May 20, 2021 Filed May 24, 2021 21:05 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 5,027 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-21-000091 · wf-form4_162189033525294.xml · nonDerivative · entry 1 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,303 F1 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of: (i) the day prior to the first anniversary of the date of grant, or (ii) the day prior to annual shareholder meeting; assuming continued service with the company. Read SEC document |
| August 07, 2020 Filed Aug 11, 2020 20:46 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 6,297 | $131.00 | $824,907.00 |
DisclosureSEC source: 0001367644-20-000130 · wf-form4_159717877286677.xml · nonDerivative · entry 1 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,276 F1 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. F2 · balance_after: Due to a computational error in the Form 4 filed on February 25, 2020, Mr. Richard's subsequently filed From 4s showed the incorrect amount of securities beneficially owned. The amount of securities beneficially owned has been corrected herein. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 20:36 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 6,572 | $87.51 | $575,142.01 |
DisclosureSEC source: 0001367644-20-000102 · wf-form4_159138937855980.xml · nonDerivative · entry 1 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,269 F1 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. F2 · price: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $87.51 to $87.58. Read SEC document |
| May 21, 2020 Filed May 26, 2020 13:13 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 2,821 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-20-000078 · wf-form4_159049877040558.xml · nonDerivative · entry 1 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,841 F1 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of: (i) the day prior to the first anniversary of the date of grant, or (ii) the day prior to annual shareholder meeting; assuming continued service with the company. Read SEC document |
| May 05, 2020 Filed May 6, 2020 21:08 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 8,375 | $80.19 | $671,628.94 |
DisclosureSEC source: 0001367644-20-000051 · wf-form4_158879930355638.xml · nonDerivative · entry 1 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,020 F1 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.0000 to $80.8660, inclusive. Read SEC document |
| April 27, 2020 Filed Apr 29, 2020 20:35 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Options (Right to Buy) · Derivative | 7,893 | $78.00 Strike: $20.08 | $615,654.00 |
DisclosureSEC source: 0001367644-20-000041 · wf-form4_158819253519592.xml · derivative · entry 3 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,893 shares Expires 2021-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Consists of options granted under the company's stock incentive plan as amended and restated. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Richard. F3 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| April 27, 2020 Filed Apr 29, 2020 20:35 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 7,893 | $78.00 | $615,654.00 |
DisclosureSEC source: 0001367644-20-000041 · wf-form4_158819253519592.xml · nonDerivative · entry 2 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,395 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Richard. Read SEC document |
| April 27, 2020 Filed Apr 29, 2020 20:35 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 7,893 | $20.08 | $158,491.44 |
DisclosureSEC source: 0001367644-20-000041 · wf-form4_158819253519592.xml · nonDerivative · entry 1 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,288 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Richard. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 21:30 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 5,152 | $18.64 Strike: $18.64 | $96,033.28 |
DisclosureSEC source: 0001367644-20-000013 · wf-form4_158266622472686.xml · derivative · entry 3 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,893 Underlying: Common Stock · 5,152 shares Expires 2021-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. F3 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. The date herein represents the third anniversary date of the grant and the final vesting date. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 21:30 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 5,152 | $65.00 | $334,880.00 |
DisclosureSEC source: 0001367644-20-000013 · wf-form4_158266622472686.xml · nonDerivative · entry 2 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,395 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Richard. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 21:30 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 5,152 | $18.64 | $96,033.28 |
DisclosureSEC source: 0001367644-20-000013 · wf-form4_158266622472686.xml · nonDerivative · entry 1 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,851 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Richard. Read SEC document |
| November 07, 2019 Filed Nov 12, 2019 14:51 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 5,153 | $18.64 Strike: $18.64 | $96,051.92 |
DisclosureSEC source: 0001367644-19-000060 · wf-form4_157357026669636.xml · derivative · entry 3 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,152 Underlying: Common Stock · 5,153 shares Expires 2021-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. F3 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. The date herein represents the third anniversary date of the grant and the final vesting date. Read SEC document |
| November 07, 2019 Filed Nov 12, 2019 14:51 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 5,153 | $60.00 | $309,180.00 |
DisclosureSEC source: 0001367644-19-000060 · wf-form4_157357026669636.xml · nonDerivative · entry 2 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,699 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Richard. Read SEC document |
| November 07, 2019 Filed Nov 12, 2019 14:51 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 5,153 | $18.64 | $96,051.92 |
DisclosureSEC source: 0001367644-19-000060 · wf-form4_157357026669636.xml · nonDerivative · entry 1 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,852 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Richard. Read SEC document |
| May 23, 2019 Filed May 29, 2019 00:11 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 5,736 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-012275 · doc1.xml · nonDerivative · entry 1 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,699 F1 · security: Consists of restricted stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of: (i) the day prior to the first anniversary of the date of grant, or (ii) the day prior to annual shareholder meeting; assuming continued service with the company. Read SEC document |
| November 07, 2018 Filed Nov 8, 2018 22:14 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,893 | $0.00 Strike: $13.00 | $0.00 |
DisclosureSEC source: 0001567619-18-005447 · doc1.xml · derivative · entry 3 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Comon Stock · 7,893 shares Expires 2020-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Richard. F3 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| November 07, 2018 Filed Nov 8, 2018 22:14 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 7,893 | $70.00 | $552,510.00 |
DisclosureSEC source: 0001567619-18-005447 · doc1.xml · nonDerivative · entry 2 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,963 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Richard. Read SEC document |
| November 07, 2018 Filed Nov 8, 2018 22:14 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 7,893 | $13.00 | $102,609.00 |
DisclosureSEC source: 0001567619-18-005447 · doc1.xml · nonDerivative · entry 1 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,856 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Richard. Read SEC document |
| August 21, 2018 Filed Aug 23, 2018 12:51 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option (Right to Bury) · Derivative | 7,793 | $14.71 Strike: $14.71 | $114,635.03 |
DisclosureSEC source: 0001567619-18-001687 · doc1.xml · derivative · entry 6 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,793 shares Expires 2020-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. F4 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| August 21, 2018 Filed Aug 23, 2018 12:51 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 7,793 | $60.02 | $467,709.36 |
DisclosureSEC source: 0001567619-18-001687 · doc1.xml · nonDerivative · entry 4 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,963 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Richard. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to 60.05, inclusive. Read SEC document |
| August 21, 2018 Filed Aug 23, 2018 12:51 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 7,793 | $14.71 | $114,635.03 |
DisclosureSEC source: 0001567619-18-001687 · doc1.xml · nonDerivative · entry 3 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Richard. Read SEC document |
| August 03, 2018 Filed Aug 23, 2018 12:51 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100 | $14.71 Strike: $14.71 | $1,471.00 |
DisclosureSEC source: 0001567619-18-001687 · doc1.xml · derivative · entry 5 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,793 Underlying: Common Stock · 100 shares Expires 2020-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. F4 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| August 03, 2018 Filed Aug 23, 2018 12:51 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 100 | $60.00 | $6,000.00 |
DisclosureSEC source: 0001567619-18-001687 · doc1.xml · nonDerivative · entry 2 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,963 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Richard. Read SEC document |
| August 03, 2018 Filed Aug 23, 2018 12:51 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 100 | $14.71 | $1,471.00 |
DisclosureSEC source: 0001567619-18-001687 · doc1.xml · nonDerivative · entry 1 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Richard. Read SEC document |
| June 06, 2018 Filed Jun 7, 2018 20:21 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 7,342 | $53.00 | $389,126.00 |
DisclosureSEC source: 0001140361-18-027686 · doc1.xml · nonDerivative · entry 1 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,963 Read SEC document |
| May 24, 2018 Filed May 24, 2018 22:28 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 4,895 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-025559 · doc1.xml · nonDerivative · entry 1 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,305 F1 · security: Consists of restricted stock units granted under the Fourth Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of (i) the day prior to the anniversary of the date of grant or (ii) one business day prior to date of the Company's next annual meeting; provided that the individual is serving on the Board on such date. Read SEC document |
| April 17, 2018 Filed Apr 19, 2018 20:49 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 7,893 | $0.00 Strike: $13.37 | $0.00 |
DisclosureSEC source: 0001140361-18-019061 · doc1.xml · derivative · entry 3 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,893 shares Expires 2019-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. F3 · derivative.exercise_date: The option grant is fully vested. Read SEC document |
| April 17, 2018 Filed Apr 19, 2018 20:49 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 7,893 | $55.00 | $434,115.00 |
DisclosureSEC source: 0001140361-18-019061 · doc1.xml · nonDerivative · entry 2 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,410 F1 · shares: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Richard. Read SEC document |
| April 17, 2018 Filed Apr 19, 2018 20:49 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 7,893 | $13.37 | $105,529.41 |
DisclosureSEC source: 0001140361-18-019061 · doc1.xml · nonDerivative · entry 1 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,303 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Richard. Read SEC document |
| December 12, 2017 Filed Dec 13, 2017 13:20 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionEmployee Stock Option (Right to buy) · Derivative | 23,681 | $0.00 Strike: $10.64 | $0.00 |
DisclosureSEC source: 0001140361-17-045941 · doc1.xml · derivative · entry 3 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,681 shares Expires 2019-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. F4 · derivative.exercise_date: The option grant is fully vested. Read SEC document |
| December 12, 2017 Filed Dec 13, 2017 13:20 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 23,681 | $45.02 | $1,066,225.18 |
DisclosureSEC source: 0001140361-17-045941 · doc1.xml · nonDerivative · entry 2 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,410 F1 · shares: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Richard. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.17, inclusive. Read SEC document |
| December 12, 2017 Filed Dec 13, 2017 13:20 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 23,681 | $10.64 | $251,965.84 |
DisclosureSEC source: 0001140361-17-045941 · doc1.xml · nonDerivative · entry 1 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,091 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Richard. Read SEC document |
| September 28, 2017 Filed Sep 29, 2017 23:04 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionEmployee Stock Option (Right to buy) · Derivative | 22,415 | $0.00 Strike: $7.99 | $0.00 |
DisclosureSEC source: 0001140361-17-037011 · doc1.xml · derivative · entry 6 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,415 shares Expires 2018-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. F4 · derivative.exercise_date: The option grant is fully vested. Read SEC document |
| September 28, 2017 Filed Sep 29, 2017 23:04 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 22,415 | $40.00 | $896,600.00 |
DisclosureSEC source: 0001140361-17-037011 · doc1.xml · nonDerivative · entry 4 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,410 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Richard. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.05, inclusive. Read SEC document |
| September 28, 2017 Filed Sep 29, 2017 23:04 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 22,415 | $7.99 | $179,095.85 |
DisclosureSEC source: 0001140361-17-037011 · doc1.xml · nonDerivative · entry 3 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,825 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Richard. Read SEC document |
| September 27, 2017 Filed Sep 29, 2017 23:04 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionEmployee Stock Option (Right to buy) · Derivative | 1,266 | $0.00 Strike: $7.99 | $0.00 |
DisclosureSEC source: 0001140361-17-037011 · doc1.xml · derivative · entry 5 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,415 Underlying: Common Stock · 1,266 shares Expires 2018-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. F4 · derivative.exercise_date: The option grant is fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.